Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 789 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SCD Clear all
Not listed Not applicable Interventional

FOCUS for Pediatric Sickle Cell Disease and Cancer

NCT04075877
View directory record Official record
Conditions
Pediatric Cancer, Sickle Cell Disease, Quality of Life, Depressive Symptoms, Coping Skills
Interventions
FOCUS
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
12 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

Haploidentical Hematopoietic Stem Cell Transplantation

NCT02165007
View directory record Official record
Conditions
Sickle Cell-thalassemia Disease, Thalassemia
Interventions
peripheral blood stem cell graft that are CD34+ selected
Drug
Lead sponsor
Catherine Bollard
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 22, 2026, 3:50 PM EDT
Recruiting Phase 2 Interventional

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

NCT02675959
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Defibrotide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
6 Months to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 3:50 PM EDT
Suspended Not applicable Interventional

SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)

NCT04589065
View directory record Official record
Conditions
Heart Failure, Chronic Systolic Heart Failure, Renal Failure, Cardiorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Not applicable Interventional

Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease

NCT03301311
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Specific Carbohydrate Diet (SCD), Modified Specific Carbohydrate Diet (MSCD)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 22, 2026, 3:50 PM EDT
Enrolling by invitation No phase listed Observational

SCRIPT: Sickle Cell Risk in Pregnancy Tool

NCT06529042
View directory record Official record
Conditions
Sickle Cell Disease, Pregnancy, High Risk, Pregnancy Complications
Interventions
Non-Interventional
Other
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
16 Years to 60 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 22, 2026, 3:50 PM EDT
Terminated No phase listed Observational

A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants

NCT06503458
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 22, 2026, 3:50 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

NCT02300558
View directory record Official record
Conditions
Long QT Syndrome Type 3
Interventions
Eleclazine, Eleclazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 22, 2026, 3:50 PM EDT
Active, not recruiting No phase listed Observational

Exploring Adherence Monitoring in Sickle Cell Disease

NCT03708731
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 3:50 PM EDT
Terminated Phase 3 Interventional Results available

Apixaban in Patients With Sickle Cell Disease

NCT02179177
View directory record Official record
Conditions
Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Nirmish Shah
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

NCT02697240
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Intravenous citrulline
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
6 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 22, 2026, 3:50 PM EDT
Completed No phase listed Observational

Carnitine Levels and Carnitine Supplementation in Type I Diabetes

NCT00351234
View directory record Official record
Conditions
Diabetes Mellitus, Type I, Hypoglycemia
Interventions
Carnitine (drug)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease

NCT01685515
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oral Decitabine and Tetrahydrouridine, Placebo
Drug
Lead sponsor
Yogen Saunthararajah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Phase 1Phase 2 Interventional

Codeine in Sickle Cell Disease

NCT00174538
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Codeine (30 mg)
Drug
Lead sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 22, 2026, 3:50 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

NCT05357482
View directory record Official record
Conditions
Sickle Cell Anemia, Beta Thalassemia
Interventions
TBI, Hydroxyurea, briquilimab, Filgrastim (G-CSF), Sirolimus, Alemtuzumab, Plerixafor
Radiation · Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

Sickle Cell Disease Conditioning for Bone Marrow Transplant

NCT00968162
View directory record Official record
Conditions
Bone Marrow Transplantation, Sickle Cell Disease
Interventions
fludarabine
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 22, 2026, 3:50 PM EDT
Recruiting No phase listed Observational

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

NCT06517810
View directory record Official record
Conditions
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Interventions
QUELIMMUNE (SCD-PED)
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
Up to 22 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 3:50 PM EDT
Active, not recruiting Not applicable Interventional

Integrative Medicine in Pain Management in Sickle Cell Disease

NCT05045820
View directory record Official record
Conditions
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
Interventions
needling acupuncture, laser acupuncture
Device
Lead sponsor
Indiana University
Other
Eligibility
14 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
Interventions
rivaroxaban, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Not applicable Interventional Results available

Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial

NCT02848781
View directory record Official record
Conditions
Ventricular Tachycardia (VT)
Interventions
Implantable Cardioverter Defibrillator (ICD), Catheter Ablation
Device · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 22, 2026, 3:50 PM EDT
Recruiting Not applicable Interventional

Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury

NCT05536076
View directory record Official record
Conditions
Sleep Apnea, SCI/D, Hypercapnia
Interventions
Hypercapnia treatment
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 22, 2026, 3:50 PM EDT
Recruiting No phase listed Observational

Left Ventricular Structural Predictors of Sudden Cardiac Death

NCT01076660
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
2
States / cities
Newark, Delaware • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 3:50 PM EDT
Not listed Phase 1 Interventional

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

NCT00343954
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline tablets, 1000 mg
Drug
Lead sponsor
Angiogenix
Industry
Eligibility
10 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2006 · Synced Oct 22, 2026, 3:50 PM EDT
Completed Not applicable Interventional

A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease

NCT04484272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support])., Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 3:50 PM EDT